ReviewACS omega2025
Bioorthogonal Cyclization Reactions for the Synthesis of Cytotoxic Drugs in Cancer Treatment.
Review in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclization reactions play a central role in the synthesis of heterocycles, many of which display potent cytotoxicity and are actively being developed as anticancer agents. Recent breakthroughs have enabled these transformations to occur in situ within living systems, thereby advancing novel bioorthogonal strategies for spatially controlled cancer therapies. This strategy enhances therapeutic efficacy by promoting the localized formation of active drugs at tumor sites, significantly reducing systemic toxicity and off-target effects. Herein, we review recent advances in the use of bioorthogonal cyclization reactions to generate cytotoxic (hetero)-cycles, including triazoles, benzotriazoles, phenanthridines, phenanthridinium salts, quinoxalines, coumarins, naphthalenes, and pyrrolizidine derivatives, directly within cancer cells. We examine the cyclization reaction classes employed, the triggers (e.g., transition metals, light, and reactive oxygen species), underlying mechanisms, and bioorthogonal strategies enabling these transformations. This Mini Review offers a focused overview of state-of-the-art methods and their therapeutic applications and highlights the transformative potential of in situ cyclization as a platform for developing next-generation, highly efficient anticancer therapies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.